FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes Kisqali (ribociclib) tablets plus Femara (letrozole) tablets, is the first combination pack with two prescription products for advanced breast cancer patients. This approval comes less than two

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *